

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

1

of

9

APPLICATION NO.: 09/337,893

ATTY. DOCKET NO.: C1039.70022US00

FILING DATE: June 21, 1999

CONFIRMATION NO.: 9627

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
<i>MM</i>	A2	6,194,388	B1	Krieg et al.	02-27-2001
<i>MM</i>	A3	6,207,646	B1	Krieg et al.	03-27-2001
<i>MM</i>	A4	6,214,806	B1	Krieg et al.	04-10-2001
<i>MM</i>	A5	6,218,371	B1	Krieg et al.	04-17-2001
<i>MM</i>	A6	6,239,116	B1	Krieg et al.	05-29-2001
<i>MM</i>	A7	6,339,068	B1	Krieg et al.	01-15-2002
<i>MM</i>	A8	6,406,705	B1	Davis et al.	06-18-2002
<i>MM</i>	A9	6,429,199	B1	Krieg et al.	08-06-2002
<i>MM</i>	A10	2001-0044416	A1	McCluskie et al.	11-22-2001
<i>MM</i>	A11	2002-0064515	A1	Krieg et al.	05-30-2002
	A12	2002-0091097	A1	Bratzler et al.	07-11-2002
	A13	2002-0156033	A1	Bratzler et al.	10-24-2002
	A14	2002-0164341	A1	Davis et al.	11-07-2002
	A15	2002-0165178	A1	Schetter et al.	11-07-2002
	A16	2002-0198165	A1	Bratzler et al.	12-26-2002
	A17	2003-0026782	A1	Krieg et al.	02-06-2003
	A18	2003-0026801	A1	Weiner et al.	02-06-2003
	A19	2003-0050261	A1	Krieg et al.	03-13-2003
	A20	2003-0050263	A1	Krieg et al.	03-13-2003
	A21	2003-0055014	A1	Bratzler	03-20-2003
	A22	2003-0091599	A1	Davis et al.	05-15-2003
	A23	2003-0100527	A1	Krieg et al.	05-29-2003
	A24	2003-0104523	A1	Bauer et al.	06-05-2003
	A25	2003-0139364	A1	Krieg et al.	07-24-2003
	A26	2003-0148316	A1	Lipford et al.	08-07-2003
	A27	2003-0148976	A1	Krieg et al.	08-07-2003
	A28	2003-0166001	A1	Lipford	09-04-2003
	A29	2003-0232074	A1	Lipford et al.	12-18-2003
	A30	2004-0009949	A1	Krieg	01-15-2004
	A31	2004-0030118	A1	Wagner et al.	02-12-2004
	A32	2004-0087534	A1	Krieg et al.	05-06-2004
	A33	2004-0087538	A1	Krieg et al.	05-06-2004
	A34	2004-0106568	A1	Krieg et al.	06-03-2004
	A35	2004-0131628	A1	Bratzler et al.	07-08-2004
<i>MM</i>	A36	2004-0132685	A1	Krieg et al.	07-08-2004
<i>MM</i>	A37	2004-0142469	A1	Krieg et al.	07-22-2004
<i>MM</i>	A38	2004-0143112	A1	Krieg et al.	07-22-2004

*NM Minnifield 2-20-05*

FORM PTO-1449/A and B (Modified)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

2

of

9

APPLICATION NO.: 09/337,893

ATTY. DOCKET NO.: C1039.70022US00

FILING DATE: June 21, 1999

CONFIRMATION NO.: 9627

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

## U.S. PATENT DOCUMENTS

A39	2004-0147468	A1	Krieg et al.	07-29-2004
A40	2004-0152649	A1	Krieg	08-05-2004
A41	2004-0152656	A1	Krieg et al.	08-05-2004
A42	2004-0152657	A1	Krieg et al.	08-05-2004
A43	2004-0162258	A1	Krieg et al.	08-19-2004
A44	2004-0162262	A1	Krieg et al.	08-19-2004
A45	2004-0167089	A1	Krieg et al.	08-26-2004
A46	2004-0171150	A1	Krieg et al.	09-02-2004
A47	2004-0171571	A1	Krieg et al.	09-02-2004
A48	5,112,605		Jardieu et al.	05-12-1992
<del>A49</del>	<del>5,804,386</del>	<del>A1</del>	<del>Carson et al.</del>	<del>09-08-1999</del>
A50	5,908,620		Tu et al.	06-01-1999
A51	5,955,059		Gilchrest et al.	09-21-1999
A52	5,994,315		Nyce et al.	11-30-1999
A53	6,025,339		Nyce et al.	02-15-2000
A54	6,030,955		Stein et al.	02-29-2000
A55	6,040,296		Nyce et al.	03-21-2000
A56	6,086,898		DeKruyff et al.	07-11-2000
A57	6,534,062	B1	Raz et al.	03-18-2003
A58	6,562,798	B1	Schwartz	05-13-2003
A59	6,787,524	B2	Chang et al.	09-07-2004
A60	2002-0086839	A1	Raz et al.	07-04-2002
A61	2002-0142977	A1	Raz et al.	10-03-2002
A62	2003-0022852	A1	Van Nest et al.	01-30-2003
A63	2003-0049266	A1	Fearon et al.	03-13-2003
A64	2003-0059773	A1	Van Nest et al.	03-27-2003
A65	2003-0064064	A1	Dina et al.	04-03-2003
A66	2003-0109469	A1	Carson et al.	06-12-2003
A67	2003-0119773	A1	Raz et al.	06-26-2003
A68	2003-0125279	A1	Junghans et al.	07-03-2003
A69	2003-0133988	A1	Fearon et al.	07-17-2003
A70	2003-0143213	A1	Raz et al.	07-31-2003
A71	2003-0147870	A1	Raz et al.	08-07-2003
A72	2003-0186921	A1	Carson et al.	10-02-2003
A73	2003-0203861	A1	Carson et al.	10-30-2003
A74	2004-0006010	A1	Carson et al.	01-08-2004
A75	2004-0006034	A1	Raz et al.	01-08-2004
A76	2004-0064064	A1	Zhou et al.	04-01-2004
A78	2004-0092468	A1	Schwartz et al.	05-13-2004

N M Minnifield 2-20-05

FORM PTO-1449/A and B (Modified)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

3

of

9

APPLICATION NO.: 09/337,893

ATTY. DOCKET NO.: C1039.70022US00

FILING DATE: June 21, 1999

CONFIRMATION NO.: 9627

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
<del>mm</del>	<del>B2</del>	<del>EP</del>	<del>0 302 758</del>	<del>A1</del>	<del>New England Medical Center Hospitals, Inc.</del>	<del>02-08-1989</del>	
<del>mm</del>	<del>B3</del>	<del>WO</del>	<del>96/40162</del>	<del>A1</del>	<del>East Carolina University</del>	<del>12-19-1996</del>	
<del>mm</del>	<del>B4</del>	<del>WO</del>	<del>98/16247</del>	<del>A1</del>	<del>The Regents of the University of California</del>	<del>04-23-1998</del>	
<del>mm</del>	<del>B5</del>	<del>WO</del>	<del>98/55495</del>	<del>A2</del>	<del>Dynavax Technologies Corporation</del>	<del>12-10-1998</del>	
<del>mm</del>	<del>B6</del>	<del>WO</del>	<del>99/11275</del>	<del>A2</del>	<del>The Regents of the University of California</del>	<del>03-11-1999</del>	
<del>mm</del>	<del>B7</del>	<del>WO</del>	<del>99/52549</del>	<del>A1</del>	<del>Smithkline Beecham Biologicals S.A.</del>	<del>10-29-1999</del>	
<del>mm</del>	<del>B8</del>	<del>WO</del>	<del>99/50118</del>	<del>A2</del>	<del>CPG Immunopharmaceuticals GmbH</del>	<del>10-10-1999</del>	
<del>mm</del>	<del>B9</del>	<del>WO</del>	<del>99/62923</del>	<del>A2</del>	<del>Dynavax Technologies Corporation</del>	<del>12-09-1999</del>	
<del>mm</del>	<del>B10</del>	<del>WO</del>	<del>00/16804</del>	<del>A1</del>	<del>Dynavax Technologies Corporation</del>	<del>03-30-2000</del>	
<del>mm</del>	<del>B11</del>	<del>WO</del>	<del>00/20039</del>	<del>A1</del>	<del>The Regents of the University of California</del>	<del>04-13-2000</del>	
<del>mm</del>	<del>B12</del>	<del>WO</del>	<del>00/54803</del>	<del>A2</del>	<del>Panacea Pharmaceuticals, LLC.</del>	<del>09-21-2000</del>	
<del>mm</del>	<del>B13</del>	<del>WO</del>	<del>00/62787</del>	<del>A1</del>	<del>The Regents of the University of California</del>	<del>10-26-2000</del>	
<del>mm</del>	<del>B14</del>	<del>WO</del>	<del>01/02007</del>	<del>A1</del>	<del>The Regents of the University of California</del>	<del>01-11-2001</del>	
<del>mm</del>	<del>B15</del>	<del>WO</del>	<del>01/12223</del>	<del>A2</del>	<del>Dynavax Technologies Corporation</del>	<del>02-22-2001</del>	
<del>mm</del>	<del>B16</del>	<del>WO</del>	<del>01/22972</del>	<del>A2</del>	<del>Coley Pharmaceuticals, GmbH</del>	<del>04-05-2001</del>	
<del>mm</del>	<del>B17</del>	<del>WO</del>	<del>02/052002</del>	<del>A2</del>	<del>Dynavax Technologies Corporation</del>	<del>07-04-2002</del>	
<del>mm</del>	<del>B18</del>	<del>WO</del>	<del>03/000232</del>	<del>A2</del>	<del>Dynavax Technologies Corporation</del>	<del>01-03-2003</del>	
<del>mm</del>	<del>B19</del>	<del>WO</del>	<del>03/015816</del>	<del>A1</del>	<del>Dynavax Technologies Corporation</del>	<del>02-27-2003</del>	
<del>mm</del>	<del>B20</del>	<del>WO</del>	<del>03/094963</del>	<del>A2</del>	<del>INEX Pharmaceuticals Corp.</del>	<del>11-20-2003</del>	
<del>mm</del>	<del>B21</del>	<del>WO</del>	<del>03/101375</del>	<del>A2</del>	<del>Immunotech SA</del>	<del>12-11-2003</del>	
<del>mm</del>	<del>B22</del>	<del>WO</del>	<del>2004/041183</del>	<del>A2</del>	<del>The Regents of the University of California</del>	<del>05-21-2004</del>	

## OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<del>mm</del>	<del>C10</del>	<del>[No Author Listed] Allergen Nomenclature, List of Allergens (as of March 12, 2004).</del>	
<del>mm</del>	<del>C11</del>	<del>[No Author Listed] Expert panel report 2: Guidelines for the diagnosis and management of asthma – Clinical practice guidelines. National Institutes of Health Publication. 1997 Jul; No. 97-4051:iii-79.</del>	
<del>mm</del>	<del>C12</del>	<del>ABED et al., Interferon-gamma regulation of B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-mediated inhibition of B cell differentiation. Cell Immunol. 1994 Feb;153(2):356-66.</del>	
<del>mm</del>	<del>C13</del>	<del>AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595-9.</del>	
<del>mm</del>	<del>C14</del>	<del>ANDERSON et al., "TH2 and 'TH2-like' cells in allergy and asthma: pharmacological perspectives", Trends in Pharmacological Science, 15: 324-332, 1994.</del>	
<del>mm</del>	<del>C15</del>	<del>ASKEW et al., "CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms", Journal of Immunology, 165: 6889-95, 2000.</del>	

N.M. Minnifield 2-20-05

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

4

of

9

APPLICATION NO.: 09/337,893

ATTY. DOCKET NO.: C1039.70022US00

FILING DATE: June 21, 1999

CONFIRMATION NO.: 9627

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

mm	C16	BAUER et al., DNA activates human immune cells through a CpG sequence-dependent manner. <i>Immunology</i> . 1999 Aug;97(4):699-705.		
mm	C17	BOHLE et al., Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. <i>Eur J Immunol</i> . 1999 Jul;29(7):2344-53.		
mm	C18	BRAZOLOT-MILLAN et al., "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice", <i>Proceedings of the National Academy of Science USA</i> , 95: 15553-15558, 1998.		
<del>mm</del>	<del>C19</del>	<del>BROIDE et al., "DNA-Based immunization for asthma", <i>International Archives of Allergy and Immunology</i>. 111: 433-456, 1999.</del>		
mm	C20	BROIDE et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. <i>J Immunol</i> . 1998 Dec 15;161(12):7054-62.		
mm	C21	BROIDE et al., Modulation of asthmatic response by immunostimulatory DNA sequences. <i>Springer Semin Immunopathol</i> . 2000;22(1-2):117-24. Review.		
mm	C22	BRUNNER et al., "Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo", <i>Journal of Immunology</i> , 165: 6278-6286, 2000.		
mm	C23	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. <i>J Exp Med</i> . 1997 Nov 17;186(10):1621-2.		
mm	C24	CELLA et al., Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. <i>Nat Med</i> . 1999 Aug;5(8):919-23.		
mm	C25	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. <i>Clin Immunol Immunopathol</i> . 1997 Aug;84(2):185-93.		
mm	C26	CHOI et al., "The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant", <i>Vaccine</i> , 20(13-14): 1733-40, 2002.		
mm	C27	DAVIS et al., "Use of CpG DNA for enhancing specific immune responses", <i>Current Topics in Microbiology Immunology</i> , 247: 171-83, 2000.		
mm	C28	DUNN et al., The three Es of cancer immunoediting. <i>Annu Rev Immunol</i> . 2004;22:329-60. Review.		
mm	C29	DURHAM et al., Immunotherapy and allergic inflammation. <i>Clin Exp Allergy</i> . 1991 Jan;21 Suppl 1:206-10.		
mm	C30	ELKINS et al., Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. <i>J Immunol</i> . 1999 Feb 15;162(4):2291-8.		
mm	C31	FRANCOIS et al., Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. <i>Clin Immunol Immunopathol</i> . 1988 Sep;48(3):297-306.		
mm	C32	FRISSORA et al., IFN-gamma-mediated inhibition of antigen receptor-induced B cell proliferation and CREB-1 binding activity requires STAT-1 transcription factor. <i>Eur J Immunol</i> . 2003 Apr;33(4):907-12.		
mm	C33	GOUTTEFANGEAS et al., Problem solving for tumor immunotherapy. <i>Nat Biotechnol</i> . 2000 May;18(5):491-2.		
mm	C34	HARTMANN et al., "CpG DNA and LPS induce distinct patterns of activation in human monocytes", <i>Gene Therapy</i> , 6: 893-903, 1999.		
mm	C35	HARTMANN et al., "Mechanism and function of a newly identified CpG DNA motif in human primary B cells", <i>Journal of Immunology</i> , 164: 944, 2000.		
mm	C36	HARTMANN et al., "Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo", <i>Journal of Immunology</i> , 164: 1617, 2000.		
	C37	HARTMANN et al., "CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells", <i>Proceedings of the National Academy of Science USA</i> , 96: 9305-9310, 1999.		
mm	C38	HAWKES et al., Times of London News International. 4M:18. Printed on September 18, 1999.		
mm	C39	HEEG et al., CpG DNA as a Th1 trigger. <i>Int Arch Allergy Immunol</i> . 2000 Feb;121(2):87-97.		
mm	C40	HOGG et al., The pathology of asthma. <i>APMIS</i> . 1997 Oct;105(10):735-45. Review.		
mm	C41	HOPKIN et al., BioMedNet, Issue 57, 6/25/1999.		
mm	C42	HORNER et al., Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. <i>J Allergy Clin Immunol</i> . 2002 Sep;110(3):413-20.		
<del>mm</del>	<del>C43</del>	<del>HUANG et al., "Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria", <i>Infection and Immunity</i>. 67(12):6257-6263, 1999.</del>		
mm	C44	IHO et al., "Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro", <i>Journal of Immunology</i> , 163: 3642, 1999.		

MM Minnifield 2-20-05

O I P E  
OCT 8 2005

FORM PTO-1449/A and B (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 09/337,893	ATTY. DOCKET NO.: C1039.70022US00
		FILING DATE: June 21, 1999	CONFIRMATION NO.: 9627
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	5	of	9

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

<i>mm</i>	C45	IKEDA et al., Microbial DNA and Host Immunity. Chapter 23: Immunostimulatory DNA for allergic asthma. p289.		
<i>mm</i>	C46	JAHNSCHMID et al., CpG oligonucleotide adjuvants modulate allergic response in mouse model. Allergy Medicine, NewsRx.com. January 16, 2000.		
<i>mm</i>	C47	JAKOB et al., "Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA", <i>Journal of Immunology</i> , 161(6): 3042-9, 1998.		
<i>mm</i>	C48	JAKOB et al., "Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses", <i>International Archives of Allergy Immunology</i> , 118(2-4): 457-61, 1999.		
<i>mm</i>	C49	JILEK et al., Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. <i>J Immunol</i> . 2001 Mar 1;166(5):3612-21.		
<i>mm</i>	C50	JUFFERMANS et al., "CpG oligodeoxynucleotides enhance host defense during murine tuberculosis", <i>Infection and Immunity</i> , 70: 147-152, 2002.		
	C51	KATAOKA et al., "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG", <i>Japan Journal of Cancer Research</i> , 83: 244-247, 1992.		
<i>mm</i>	C52	KITAGAKI et al., Microbial DNA and Host Immunity. Chapter 24. page 301.		
	C53	KLINMAN et al., Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. <i>J Immunol</i> . 1998 Mar 15;160(6):2555-9.		
<i>mm</i>	C54	KLINMAN et al., Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. <i>Am J Physiol Lung Cell Mol Physiol</i> . 2002 Jul;283(1):L170-9.		
<i>mm</i>	C55	KLINMAN et al., CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. <i>J Allergy Clin Immunol</i> . 1999 Sep;104(6):1258-64.		
<i>mm</i>	C56	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. <i>Drug News Perspect</i> . 2000 Jun;13(5):289-96.		
<i>mm</i>	C57	KLINMAN et al., "Immune recognition of foreign DNA: a cure for bioterrorism?", <i>Immunity</i> , 11: 123-129, 1999.		
<i>mm</i>	C58	KLINMAN et al., "Contribution of CpG motifs to the immunogenicity of DNA vaccines", <i>Journal of Immunology</i> , 158(8): 3635-9, 1997.		
<i>mm</i>	C59	KOHAMA et al., Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. <i>J Allergy Clin Immunol</i> . 1999 Dec;104(6):1231-8.		
<i>mm</i>	C60	KOU et al., <i>Alerugi</i> , 43: 482, 1994. Abstract only		
<i>mm</i>	C61	KOVARIK et al., "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming", <i>The Journal of Immunology</i> , 162: 1611-1617, 1999.		
<i>mm</i>	C62	KRANZER et al., "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming", <i>Immunology</i> , 99: 170, 2000.		
<i>mm</i>	C63	KRIEG et al., "Immune effects and therapeutic applications of CpG motifs in bacterial DNA", <i>Immunopharmacology</i> , 48: 293-305, 2000.		
	C64	KRIEG et al., American College of Rheumatology 58th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. <i>Arthritis Rheum</i> . 1994 Sep;37(9 Suppl).		
<i>mm</i>	C65	KRIEG et al., CpG motifs in bacterial DNA and their immune effects. <i>Annu Rev Immunol</i> . 2002;20:709-60. Epub 2001 Oct 04.		
<i>mm</i>	C66	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. <i>Immunol Today</i> . 2000 Oct;21(10):521-6.		
<i>mm</i>	C67	KRIEG et al., 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996: p116.		
<i>mm</i>	C68	KRIEG et al., "Enhancing vaccines with immune stimulatory CpG DNA", <i>Current Opinions Molecular Theory</i> , 3(1): 15-24, 2001.		
<i>mm</i>	C69	KRIEG et al., Ernst Schering Research Found Workshop, (30): 105-18, 2001.		
<i>mm</i>	C70	KRIEG et al., "Immune effects and mechanisms of action of CpG motifs", <i>Vaccine</i> , 19(6): 618-22, 2001.		
<i>mm</i>	C71	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. <i>Biochim Biophys Acta</i> . 1999 Dec 10;1489(1):107-16.		
<i>mm</i>	C72	KRIEG et al., The CpG motif: Implications for clinical immunology. <i>BioDrugs</i> . 1998 Nov 1;10(5):341-6.		

*NM Minnifield 2-20-05*

FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet 6 of 9

APPLICATION NO.: 09/337,893

ATTY. DOCKET NO.: C1039.70022US00

FILING DATE: June 21, 1999

CONFIRMATION NO.: 9627

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

mm	C73	KRIEG et al., Immune stimulation by oligonucleotides. In Antisense Research and Application. S. T. Crooke, editor. Springer, Heidelberg. 1998: 471-515.		
mm	C74	KRIEG et al., "The role of CpG motifs in innate immunity", <i>Current Opinions Immunology</i> , 12: 35, 2000.		
mm	C75	KRIEG et al., "Mechanism of Action in CpG DNA", <i>Current Topics in Microbiology and Immunology</i> , 247: 1-21, 2000.		
mm	C76	KRIEG et al., "Mechanisms and therapeutic applications of immune stimulatory cpG DNA", <i>Pharmacology and Therapeutics</i> , 84: 113, 1999. <b>113-120</b>		
mm	C77	KRIEG et al., "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs", <i>Proceedings of the National Academy of Science</i> , 95: 12631-636, 1998.		
mm	C78	KRIEG et al., "CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>Listeria monocytogenes</i> challenge", <i>Journal of Immunology</i> , 161(5): 2428-2434, 1998.		
mm	C79	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.		
mm	C80	KRIEG, Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.		
mm	C81	KUBY et al., Immunology, Second Edition. 1991, W.H. Freeman and Company, United States of America. Chapter 13: Cytokines.		
mm	C82	KURAMOTO et al., "Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction", <i>International Immunopharmacology</i> , 14(5): 773-782, 1992.		
mm	C83	LeCLERC et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol. 1997 Aug 1;179(2):97-106.		
mm	C84	LEIBSON et al., Role of gamma-interferon in antibody-producing responses. Nature. 1984 Jun 28-Jul 4;309(5971):799-801.		
mm	C85	LIPFORD et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", <i>European Journal of Immunology</i> , 27(9): 2340-4, 1997.		
mm	C86	LIPFORD et al., "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines", <i>European Journal of Immunology</i> , 27: 3420-6, 1997.		
mm	C87	LIPFORD et al., "CpG DNA as an immune adjuvant", <i>Trends Microbiological</i> , 6(12): 495-500, 1998.		
mm	C88	LOTZ et al., Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus. J Rheumatol. 1987 Feb;14(1):42-5.		
mm	C89	MA et al., DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine. 2002 Sep 10;20(27-28):3263-71.		
mm	C90	MARDH et al., Alternaria alternata as a cause of opportunistic fungal infections in man. Scand J Infect Dis Suppl. 1978;(16):36-40.		
mm	C91	MARSHALL et al., Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol. 2001 Aug;108(2):191-7.		
mm	C92	MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol. 1999 Jul;11(7):1111-8.		
mm	C93	MCCLUSKIE et al., "CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice", <i>Journal of Immunology</i> , 161: 4463-6, 1998.		
mm	C94	MCCLUSKIE et al., CpG DNA as mucosal adjuvant. Vaccine, 18: 231-237, 2000.		
mm	C95	MCCLUSKIE et al., "Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants", <i>Vaccine</i> , 19: 413-422, 2001.		
mm	C96	MCCLUSKIE et al., "CpG DNA is an effective oral adjuvant to protein antigens in mice", <i>Vaccine</i> , 19(7-8):950-7, 2001.		
mm	C97	MCCLUSKIE et al., "The use of CpG DNA as a mucosal vaccine adjuvant", <i>Current Opinions Investigational Drugs</i> , 2(1): 35-9, 2001.		
mm	C98	MCCLUSKIE et al., "The role of CpG in DNA vaccines", <i>Springer Seminars in Immunopathology</i> , 22(1-2): 125-32, 2000.		
mm	C99	METZGER et al., Enhancement of humoral immunity by interleukin-12. Ann N Y Acad Sci. 1996 Oct 31;795:100-15.		
mm	C100	MOND et al., Recombinant interferon-gamma inhibits the B cell proliferative response stimulated by soluble but not by Sepharose-bound anti-immunoglobulin antibody. J Immunol. 1985 Oct;135(4):2513-7.		

N M Minnifield 2-20-05

FORM PTO-1449/A and B (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 09/337,893	ATTY. DOCKET NO.: C1039.70022US00
		FILING DATE: June 21, 1999	CONFIRMATION NO.: 9627
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	7	of	9

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

<i>mm</i>	C101	MOSMANN et al., The expanding universe of T-cell subsets: Th1, Th2 and more. <i>Immunol Today</i> . 1996 Mar;17(3):138-46. Review.		
<i>mm</i>	C102	PARK et al. "Adjuvant effect of polyadenylic.polyuridylic acid on antibody production of recombinant hepatitis B surface antigen in mice", <i>International Journal of Immunopharmacology</i> , 17(6): 513, 1995.		
<i>mm</i>	C103	PARRONCHI et al., Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors. <i>J Immunol</i> . 1999 Dec 1;163(11):5946-53.		
<i>mm</i>	C104	PAYETTE et al., "History of vaccines and positioning of current trends", <i>Current Drugs Targets for Infection and Disorders</i> , 1(3): 241-7, 2001.		
<i>mm</i>	C105	PENG et al., CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice. <i>Int Immunol</i> . 2001 Jan;13(1):3-11.		
<i>mm</i>	C106	PISETSKY et al., "The influence of base sequence on the immunostimulatory properties of DNA", <i>Immunity Research</i> , 19: 35-46, 1999.		
<i>mm</i>	C107	PISETSKY et al., Immunological properties of bacterial DNA. <i>Ann N Y Acad Sci</i> . 1995 Nov 27;772:152-63. Review.		
<i>mm</i>	C108	RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. <i>Antisense Nucleic Acid Drug Dev</i> . 2001 Oct;11(5):333-40.		
<i>mm</i>	C109	RAY et al., <i>Faseb J</i> . 2001; 15(5):A1007. <i>Abstract only</i>		
<i>mm</i>	C110	RAZ et al., Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. <i>Proc Natl Acad Sci U S A</i> . 1994 Sep 27;91(20):9519-23.		
<i>mm</i>	C111	REYNOLDS et al., Inhibition of B lymphocyte activation by interferon-gamma. <i>J Immunol</i> . 1987 Aug 1;139(3):767-73.		
<i>mm</i>	C112	RICCI et al., T cells, cytokines, IgE and allergic airways inflammation. <i>J Investig Allergol Clin Immunol</i> . 1994 Sep-Oct;4(5):214-20. Review.		
<i>mm</i>	C113	ROBINSON et al., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. <i>N Engl J Med</i> . 1992 Jan 30;326(5):298-304.		
<i>mm</i>	C114	SANDRASAGRA et al., Discovery and development of respirable antisense therapeutics for asthma. <i>Antisense Nucleic Acid Drug Dev</i> . 2002 Jun;12(3):177-81. Review.		
<i>mm</i>	C115	SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. <i>J Immunol</i> . 1999 Jul 1;163(1):224-31.		
<i>mm</i>	C116	SCHWARTZ et al., "CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract", <i>Journal of Clinical Investigation</i> , 100(1): 68-73, 1997.		
<i>mm</i>	C117	SIDMAN et al., Gamma-interferon is one of several direct B cell-maturing lymphokines. <i>Nature</i> . 1984 Jun 28-Jul 4;309(5971):801-4.		
<i>mm</i>	C118	SPARWASSER et al., Bacterial DNA causes septic shock. <i>Nature</i> . 1997 Mar 27;386(6623):336-7.		
<i>mm</i>	C119	SPIEGELBERG et al., DNA-based approaches to the treatment of allergies. <i>Curr Opin Mol Ther</i> . 2002 Feb;4(1):64-71.		
<i>mm</i>	C120	STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? <i>Science</i> . 1993 Aug 20;261(5124):1004-12. Review.		
<i>mm</i>	C121	STUART et al., Start-Up. April, 1999. 12-20.		
<i>mm</i>	C122	SUN et al. "Type I interferon-mediated stimulation of T cells by CpG DNA", <i>Journal of Experimental Medicine</i> , 188: 2335, 1998.		
<i>mm</i>	C123	SUN et al. "Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons", <i>Springer Seminars in Immunopathology</i> , 22: 77, 2000.		
<i>mm</i>	C124	SUR et al., Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. <i>J Immunol</i> . 1999 May 15;162(10):6284-93.		
<i>mm</i>	C125	THREADGILL et al., "Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide", <i>Vaccine</i> , 16(1): 75-82, 1998.		
<i>mm</i>	C126	TIGHE et al., Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. <i>J Allergy Clin Immunol</i> . 2000 Jul;106(1 Pt 1):124-34.		
<i>mm</i>	C127	TORTORA et al., Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. <i>Clin Cancer Res</i> . 2000 Jun;6(6):2506-12.		
<i>mm</i>	C128	TOURNOY et al., Is Th1 the solution for Th2 in asthma? <i>Clin Exp Allergy</i> . 2002 Jan;32(1):17-29. Review.		
<i>mm</i>	C129	UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. <i>Curr Opin Drug Discov Devel</i> . 2003 Mar;6(2):204-17.		

*N M Minnifield 2-20-05*



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

8

of

9

APPLICATION NO.: 09/337,893

ATTY. DOCKET NO.: C1039.70022US00

FILING DATE: June 21, 1999




























CONFIRMATION NO.: 9627

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

	C130	VOLLMER et al., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. <i>Antisense Nucleic Acid Drug Dev.</i> 2002 Jun;12(3):165-75.		
	C131	VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. <i>Eur J Immunol.</i> 2004 Jan;34(1):251-62.		
	C132	WAGNER, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. <i>Curr Opin Microbiol.</i> 2002 Feb;5(1):62-9.		
	C133	WALLNER et al., Immunotherapy with T-cell-reactive peptides derived from allergens. <i>Allergy.</i> 1994 May;49(5):302-8. Review.		
	C134	WEERATNA et al., Optimization strategies for DNA vaccines. <i>Intervirology.</i> 2000;43(4-6):218-26.		
	C135	WEERATNA et al., "CpG DNA induces stronger immune responses with less toxicity than other adjuvants", <i>Vaccine</i> , 18(17): 1755-62, 2000.		
	C136	WEERATNA et al., "Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides", <i>Antisense &amp; Nucleic Drug Development</i> , 8: 351-356, 1998.		
	C137	WEERATNA et al., "CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice", <i>FEMS Immunology Medicine Microbiology</i> , 32(1): 65-71, 2001.		
	C138	WEINER et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization", <i>Proceedings of the National Academy of Science USA</i> , 94(20): 10833-7, 1997.		
	C139	WERNETTE et al., "CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation", <i>Veterinary Immunology and Immunopathology</i> , 84(3-4): 223-236, 2002.		
	C140	WHALEN et al., DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. <i>Ann N Y Acad Sci.</i> 1995 Nov 27;772:64-76. Review.		
	C141	WYATT et al., "Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion", <i>Proceedings of the National Academy of Science USA</i> , 91: 1356-60, 1994.		
	C142	YI et al., "Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA", <i>Journal of Immunology</i> , 161: 4493, 1998.		
	C143	YI et al., "Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway", <i>Journal of Immunology</i> , 157: 5394-5402, 1996.		
	C144	YI et al., "CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry", <i>Journal of Immunology</i> , 160: 5898, 1998.		
	C145	ZHANG et al., Antigen- and isotype-specific immune responses to a recombinant antigen-allergen chimeric (RAAC) protein. <i>J Immunol.</i> 1993 Jul 15;151(2):791-9.		
	C146	ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):495-502.		
	C147	Patent Interference No. 105,171. Miscellaneous Motion 1 (Unopposed Additional Request for Copies of File Histories). April 15, 2004.		
	C148	Patent Interference No. 105,171. Miscellaneous Motion 2 (Unopposed Request for Addition to Iowa's File History). April 15, 2004.		
	C149	Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for Judgment Based on Failure to Comply with 35 U.S.C. 135(b)) (Electronically filed, unsigned). June 7, 2004.		
	C150	Patent Interference No. 105,171. Iowa Preliminary Motion 4 (For Judgment of No Interference in Fact) (Electronically filed, unsigned). June 7, 2004.		
	C151	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (For Judgment Based on Lack of Enablement) (Electronically filed, unsigned). June 7, 2004.		
	C152	Patent Interference No. 105,171. Iowa Preliminary Motion 6 (For Judgment Based Lack of an Adequate Written Description) (Electronically filed, unsigned). June 7, 2004.		
	C153	Patent Interference No. 105,171. Iowa Preliminary Motion 7 (Motion to Redefine the Interference to Designate Claims as Not Corresponding to the Count) (Electronically filed, unsigned). June 7, 2004.		
	C154	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (Contingent Motion to Redefine Count) (Electronically filed, unsigned). June 7, 2004.		
	C155	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (Motion for Benefit of Earlier Application) (Electronically filed, unsigned). June 7, 2004.		
	C156	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (Contingent Motion to Redefine the Interference By Adding A Continuation Application) (Electronically filed, unsigned). July 2, 2004.		
	C157	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.		

*NM Minnifield* 2-20-05



FORM PTO-1449/A and B (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 09/337,893	ATTY. DOCKET NO.: C1039.70022US00
		FILING DATE: June 21, 1999	CONFIRMATION NO.: 9627
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	9	of	9

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

<i>M</i>	C158	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (To Designate Additional Claims of the Iowa Patent as Corresponding to the Count). June 7, 2004.		
<i>M</i>	C159	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (For Judgment Based on Lack of Written Description Support and Introducing New Matter). June 7, 2004.		
<i>M</i>	C160	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (For Judgement Based on Anticipation). June 7, 2004.		
<i>M</i>	C161	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (For Judgment Based on Obviousness). June 7, 2004.		
<i>M</i>	C162	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (For Judgement Based on Anticipation). June 7, 2004.		
<i>M</i>	C163	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (For Judgment Based on Inequitable Conduct). June 7, 2004.		
<i>M</i>	C164	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 7 (For Benefit of an Earlier Application under 37 CFR 1.633(j)). July 2, 2004.		
<i>M</i>	C165	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 8 (To Add Additional Claims Under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.		
<i>M</i>	C166	Amended Claims for Application Number 09/265,191, filed March 10, 1999.		

EXAMINE R <i>NM. Minnifield</i>	DATE CONSIDERED <i>2-20-05</i>
---------------------------------	--------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

O I P E

FORM PTO-1449/A and B (Modified) OCT 28 2004

APPLICATION NO.: 09/337,893		ATTY. DOCKET NO.: C1039.70022US00	
FILING DATE: June 21, 1999		CONFIRMATION NO.: 9627	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
APPLICANT: Krieg et al.			
GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	1	of	3

#### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		2004-0181045	A1	Krieg et al.	09-16-2004
		2004-0198688	A1	Krieg et al.	10-07-2004

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
M		Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.		
M		Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.		
M		Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.		
M		Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.		
M		Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.		
M		Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.		
M		Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(i)) (Electronically filed, unsigned). September 9, 2004.		
M		Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633(2) and (i)) (Electronically filed, unsigned). September 9, 2004.		
M		Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.		
M		Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.		
M		Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.		
M		Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.		
M		Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004.		
M		Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.		
M		Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.		
M		Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.		
M		Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.		
M		Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.		
M		Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.		

*NM Minnifield 2-20-05*

FORM PTO-1449/A and B (Modified) <b>OCT 28 2004</b>		APPLICATION NO.: 09/337,893	ATTY. DOCKET NO.: C1039.70022US00
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		FILING DATE: June 21, 1999	CONFIRMATION NO.: 9627
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	2	of	3

	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004.		
	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.		
	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.		
	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.		
	Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.		
	Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.		
	Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.		
	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.		
	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.		
	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.		
	Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.		
	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.		
	CAPRON et al., Immunologic aspects of schistosomiasis. Annu Rev Med. 1992;43:209-18. Review. Exhibit 2068.		
	KRUG et al., Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct;31(10):3026-37.		
	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract Number 615.		
	SANTELIZ et al., Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol. 2002 Mar;109(3):455-62. Exhibit 1041.		
	TOKUNGA, Response of the organism to DNA - With a focus on immunostimulatory DNA. Kansen Ensho Meneki. 2001 Autumn; 31(3): 1-12. Japanese. Exhibits 1048 and 1049.	Yes	
	VLASSOV et al., Oligonucleotides in cells and in organisms: pharmacological considerations. in Prosepects for Antisense Nucleic Acid Therapy of Cancer and AIDS. 1991: 243-66.		
	YAMAMOTO, Cytokine production inducing action of oligo DNA. Rinsho Meneki. 1997; 29(9): 1178-84. Japanese. Exhibits 1050, 1047, and 1046.	Yes	
	ZIMMERMANN et al., CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol. 1998 Apr 15;160(8):3627-30.		
	[No Author Listed] DNA is the primary genetic material. in Recombinant DNA, Second Edition. Watson et al., editors. Scientific American Books, New York. p24-5, 147. Exhibit 1003.		
	[No Author Listed] Definitions. in The Dictionary of Immunology, Fourth Edition. Herbert et al., editors. Academic Press, 1995. p10. Exhibit 1004.		
	[No Author Listed] <a href="http://www.doctorfungus.com/the_fungi/Cryptococcus.htm">http://www.doctorfungus.com/the_fungi/Cryptococcus.htm</a> . Exhibit 1029.		
	[No Author Listed] <a href="http://www.doctorfungus.com/the_fungi/Blastomyces.htm">http://www.doctorfungus.com/the_fungi/Blastomyces.htm</a> . Exhibit 1030.		

*N M Minnifield 2-20-05*

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/337,893	ATTY. DOCKET NO.: C1039.70022US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 21, 1999	CONFIRMATION NO.: 9627
APPLICANT: Krieg et al.			
GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	3	of	3

<i>mm</i>	[No Author Listed] <a href="http://www.doctorfungus.com/the_fungi/Alternaria.htm">http://www.doctorfungus.com/the_fungi/Alternaria.htm</a> . Exhibit 1031.		
<i>mm</i>	[No Author Listed] <a href="http://www.cancer.gov/newscenter/pressreleases/cancervaccines/print">http://www.cancer.gov/newscenter/pressreleases/cancervaccines/print</a> . Exhibit 1042.		
<i>mm</i>	[No Author Listed] <a href="http://www.cancer.gov/clinicaltrials/learning/cancervaccines/print">http://www.cancer.gov/clinicaltrials/learning/cancervaccines/print</a> . Exhibit 1043.		
<i>mm</i>	[No Author Listed] Recombinant DNA Technology. in Molecular Biology of the Cell. Alberts et al., editors. Garland Publishing, Inc. 1983. Exhibit 2027.		
<i>mm</i>	[No Author Listed] Definitions. in Dorland's Illustrated Medical Dictionary, Twenty-sixth Edition. W.B. Saunders Company, 1981. Exhibit 2032.		
<i>mm</i>	[No Author Listed] Macromolecules in Prokaryotic and Eukaryotic Cells. in Molecular Cell Biology, Darnell et al, Editors. W.H. Freeman and Company, 1986. Exhibit 2033.		
<i>mm</i>	[No Author Listed] Definitions. in Immunology, Roitt et al., Editors. Gower Medical Publishing Company, 1985. Exhibit 2035.		
<i>mm</i>	[No Author Listed] Definitions. in Webster's New Collegiate Dictionary. The G&C Merriam Company, 1981. p287. Exhibit 2070.		
<i>mm</i>	[No Author Listed] <a href="http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Cancer_Vaccines_Active_Specific_Immunotherapies.asp">http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Cancer_Vaccines_Active_Specific_Immuntherapies.asp</a> . Exhibit 2072.		
<i>mm</i>	[No Author Listed] <a href="http://www.plwc.org/plwc/mainconstructor">http://www.plwc.org/plwc/mainconstructor</a> . Exhibit 2073.		
<i>mm</i>	[No Author Listed] <a href="http://www.icare.org/treatment/tcwvt4.htm">http://www.icare.org/treatment/tcwvt4.htm</a> . Exhibit 2074.		

EXAMINER: <i>N. M. Minnifield</i>	DATE CONSIDERED: <i>2-20-05</i>
--------------------------------------	------------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]